Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence |
Breast Neoplasms | Austria Germany |
NCT06830720 | |
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation |
HR+HER2- Advanced Breast Cancer | Russia | NCT06625333 | |
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study |
Metastatic Castration-Resistant Prostate Cancer | Phase1 | Germany Netherlands Spain Switzerland United Kingdom United States View all |
NCT06531499 |
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer |
Breast Cancer | Jordan Oman Saudi Arabia United Arab Emirates View all |
NCT06075758 | |
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. |
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase1 | Belgium China France Germany Israel Italy Japan Norway Singapore South Korea Spain Sweden Taiwan United Kingdom United States View all |
NCT05838768 |
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
Breast Cancer | Phase1 | China France Germany Poland Portugal Spain United States View all |
NCT05870579 |
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers |
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms | Phase1 | Canada China France Germany Hong Kong Italy Japan Singapore South Korea Spain Taiwan United States View all |
NCT05544929 |
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers |
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | Phase1 | Belgium Canada France Germany Israel Italy Netherlands Spain Switzerland United States View all |
NCT06562192 |
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. |
Metastatic Neuroendocrine Prostate Cancer | Phase1 | France Germany Italy Spain United Kingdom United States View all |
NCT06379217 |
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer |
Prostate Cancer | Phase4 | Austria Belgium Canada Czechia France Germany Netherlands Spain Sweden United Kingdom United States View all |
NCT05803941 |